B-cells have recently been successfully targeted in autoimmune diseases. Indeed, depletion of the mature B-cell pool with cytotoxic antibodies directed against CD20/CD19 and antagonism of the B-cell activating factor from the TNF family led to drug approval in several diseases. Notably, this success was achieved with reagents not impacting directly the autoantibody-secreting effector plasmocytes. Here, we are listing the candidate targets that may be used to deplete plasmocytes. We are also discussing the benefits provided to autoimmunity by such putative treatments.